Can I read Immunomodulatory kits generating leukaemia derived dendritic cells do not induce blast proliferation ex vivo: IPO-38 as a novel marker to quantify proliferating blasts in acute myeloid leukaemia on EtoBox?

Immunomodulatory kits generating leukaemia derived dendritic cells do not induce blast proliferation ex vivo: IPO-38 as a novel marker to quantify proliferating blasts in acute myeloid leukaemia by Caroline Plett; Lara Kristina Klauer; Daniel Christoph Amberger; Selda Ugur; Alexander Rabe; Zuzana Fischer; Diana Deen; Annika Hirn-Lopez; Carina Gunsilius; Jan-Ole Werner; Jörg Schmohl; Doris Krämer; Andreas Rank; Christoph Schmid; Helga Maria Schmetzer is a Immunology and Microbiology article available to read on EtoBox.

What is Immunomodulatory kits generating leukaemia derived dendritic cells do not induce blast proliferation ex vivo: IPO-38 as a novel marker to quantify proliferating blasts in acute myeloid leukaemia about?

(Leukaemia derived) dendritic cells (DC, DC) are potent stimulators of anti-leukaemic activity in acute myeloid leukaemia (AML) and can be generated with immunomodulatory kits containing granulocyte-macrophage-colony-stimulating-factor (GM-CSF), prostaglandin-E (PGE), prostaglandin-E (PGE) and/or picibanil (OK-321). Potential adverse effects initiated through kits, especially the proliferation of blasts, must be ruled out to ensure treatment safety. We quantified proliferating blasts with the proliferation markers CD71 and Ki-67 and the novel proliferation marker IPO-38 before and after kit treatment ex vivo. IPO-38 hereby appeared to be the most sensitive marker; a combination with CD71 may add value when assessing proliferation kinetics. Kit treatment did not or only slightly (<5%) induce blast proliferation in most cases. An induction of blast proliferation was only found in single cases and could be compensated by DC-induced anti-leukaemic activity in most times. Overall, we appraise kit treatment to be safe in vivo.

Who reads Immunomodulatory kits generating leukaemia derived dendritic cells do not induce blast proliferation ex vivo: IPO-38 as a novel marker to quantify proliferating blasts in acute myeloid leukaemia?

Author

Caroline Plett; Lara Kristina Klauer; Daniel Christoph Amberger; Selda Ugur; Alexander Rabe; Zuzana Fischer; Diana Deen; Annika Hirn-Lopez; Carina Gunsilius; Jan-Ole Werner; Jörg Schmohl; Doris Krämer; Andreas Rank; Christoph Schmid; Helga Maria Schmetzer

Publisher

Elsevier BV

Published

2022

Language

EN

Field

Immunology and Microbiology (Life Sciences)